HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wayne, G. F. Search for Related Content PubMed PubMed Citation Articles by Wayne, G. F. Related Collections Smoking Tobacco use

Potential reduced exposure products (PREPs) in industry trial testimony

Correspondence to:
Geoffrey Ferris Wayne
PO Box 183, Albion, CA 95410, USA; ferriswayne{at}gmail.com

Objective: To identify patterns in trial testimony that may reflect on the intentions or expectations of tobacco manufacturers with regard to the introduction of potential reduced exposure products (PREPs).

Design: Research was conducted using the Deposition and Trial Testimony Archive (DATTA) collection of trial testimony and depositions housed online at Tobacco Documents Online (www.tobaccodocuments.org). Relevant testimony was identified through full-text searches of terms indicating PREPs or harm reduction strategies. The role and function of PREPs in testimony were classified according to common and contrasting themes. These were analysed in the context of broader trial arguments and against changes in time period and the market.

Results: Analysis of testimony suggests that the failure of PREPs in the market tempered initial industry enthusiasm and made protection of the conventional cigarette market its major priority. The "breakthrough" character of PREPs has been de-emphasised, with trial arguments instead positioning PREPs as simply another choice for consumers. This framework legitimises the sale of conventional brands, and shifts the responsibility for adoption of safer products from the manufacturer to the consumer. Likewise, testimony has abandoned earlier dramatic health claims made with regard to PREPs, which had undermined industry arguments regarding efforts to reduce harm in conventional products. More recent testimony advocates the broad acceptance of independent guidelines that would validate use of health claims and enable the industry to market PREPs to consumers.

Conclusion: Trial testimony reflects the changing role and positioning of PREPs by the tobacco industry. The findings are of particular importance with regard to future evaluation and potential regulation of reduced harm products.

Abbreviations: DATTA, Deposition and Trial Testimony Archive; FTC, Federal Trade Commission; IOM, Institute of Medicine; PM, Philip Morris; PREPs, potential reduced exposure products; R&D, research and development; RJR, RJ Reynolds; TSNA, tobacco specific nitrosamines

Keywords: harm reduction; potential reduced exposure products; PREPs; product safety; trial testimony; trials

This article has been cited by other articles:

				D D. Blanke and H. H Humphrey III Putting truth into action: using the evidence for justice Tob. Control, December 1, 2006; 15(suppl_4): iv1 - iv3. [Full Text] [PDF]